Trxade Group (NASDAQ:MEDS) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.08) by 62.5 percent. This is a 23.53 percent increase over losses of $(0.17) per share from the same period last year.
Kala Pharmaceuticals Announces FDA Acceptance Of IND Application For KPI-012 For The Treatment Of PCED; Received Remaining $25M Investment Under Previously Announced Private Placement Financing
On-track to initiate Phase 2b trial in 1Q 2023; Topline data expected in 1Q 2024 --
-- Received remaining $25 million investment under previously announced private placement financing --
